Spectral properties of methyl-2-cis-lachnophyllate

D. Sadyrbekov,O. Ryazantsev,B. Kenesov,V. Raldugin,G. Atazhanova,S. Adekenov

DOI: https://doi.org/10.1007/s10600-006-0191-6

2006-07-01

Chemistry of Natural Compounds

Abstract:

What problem does this paper attempt to address?

CHARACTERIZATION OF FRACTURES AND MULTIPHASE FLOW IN FRACTURED PERMEABLE ROCKS USING NMR IMAGING TECHNIQUES

Songhua Chen,X. Yao,J. Qiao,A. T. Watson

Abstract:A new noninvasive method is presented for laboratory characterization of fractures in permeable media using relaxation-weighted NMR imaging techniques. The method is based on the fact that relaxation rates in fractures and those in surrounding porous matrix are substantially different. Thus, by selectively suppressing imaging signals from either fractures or porous matrix, one can highlight fluid distributions in either of these regions so that fractures can be unambiguously identified and surrounding porous structures can be characterized. The advantages over conventional NMR spin-echo imaging are demonstrated. We also demonstrate that the technique can be used to speed acquisitions of images of fluid distributions in porous matrix. In addition, a two-phase displacement experiment was conducted to investigate transport features related to fractured systems.
Clinical observation of the moxibustion stimulation and moxibustion effect in treating allergic rhinitis on Shangyintang acupoint by mild-warm moxibustion

ZHANG Hai-feng,LU Wei,KANG Ming-fei,HUANG Xian-bao,FU Yong

2017-01-01

Abstract:Objective:To compare different moxibustion stimulation (heat-sensitive moxibustion stimulation vs non-heat-sensitive moxibustion stimulation) on Shangyintang acupoint in the treatment of allergic rhinitis.Methods:A total of 60 patients with allergic rhinitis were divided into heat-sensitive moxibustion and non-heat-sensitive moxibustion groups in accordance with their reactions to moxa-heat stimulation.Mild-warm moxibustion was distanced from skin 2-3cm and applied to bilateral Shangyintang acupoint for 45 minutes.The degree was warm but not hot.Moxibustion treatment was conducted once daily for 20 days.Patients with occurrence of heat-sensitivity being equal to and more than 3 times during the treatment were assigned to heat-sensitive group and those with occurrence of heat-sensitivity less than 3 times assigned to non-heat-sensitive group.The changes of clinical symptoms before and after treatment in two groups were observed.Results:The nasal symptoms scores of the two groups were lower than those before the treatment (P＜0.05),and the heat-sensitive group was better than the non-heatsensitive group (P＜0.05);the effective rate of the heat-sensitive group was 73.53％,compared with the non-heat-sensitive group,the difference was statistically significant (P＜0.05).Conclusion:Heat-sensitive moxibustion is significantly better than nonheat-sensitive moxibustion in the treatment of allergic rhinitis.The emergence of the heat-sensitivity to moxibustion is the key to improve the curative effect of moxibustion therapy.
Moxibustion for Essential Hypertension and Hypertensive Symptoms: A Systematic Review of 18 Randomized Controlled Trials

Xu Zhou,Qingni Wu,Meilu Liu,Weifeng Zhu,Qing Ren,Yanping Wang,Xin Sun,Jianrong Chen

DOI: https://doi.org/10.1159/000513701

2021-01-01

Complementary Medicine Research

Abstract:Introduction: This systematic review aims to update the evidence for moxibustion for essential hypertension. Methods: Randomized controlled trials (RCTs) comparing moxibustion versus lifestyle intervention or moxibustion plus antihypertensive drugs versus antihypertensive drugs alone were searched in 9 databases up to March 29, 2020. In meta-analyses, mean difference (MD) and proportional odds ratio (pOR) with 95% confidence intervals (CIs) was pooled for continuous and ordinal outcomes, respectively. Results: Eighteen RCTs were included, involving 1,460 patients. Moxibustion decreased systolic (MD –7.85 mm Hg, 95% CI –9.69 to –6.00, p < 0.00001, I 2 = 46%) and diastolic (MD –4.09 mm Hg, 95% CI –5.45 to –2.73, p < 0.0001, I 2 = 56%) blood pressures and improved the response to hypotensive treatment (pOR 2.37, 95% CI 1.49–3.75, p = 0.0003, I 2 = 57%) significantly more than did the control treatment. Moxibustion also significantly relieved headache and dizziness but the effects changed to be statistically nonsignificant after excluding RCTs with a high risk of bias. Moxibustion did not significantly relieve insomnia and anxiety. No adverse events were reported. Conclusions: Based on the current low to moderate quality evidence, our study suggests that moxibustion may have effects on reducing blood pressure. The effects of moxibustion on typical hypertension symptoms and the long-term safety of moxibustion remain uncertain.

integrative & complementary medicine
What is epidemic intelligence, and how is it being improved in Europe?

R. Kaiser,D. Coulombier,M. Baldari,D. Morgan,C. Paquet

DOI: https://doi.org/10.2807/ESW.11.05.02892-EN

2006-02-02

Abstract:‘Epidemic intelligence’ can be defined as all the activities related to early identification of potential health threats, their verification, assessment and investigation in order to recommend public health measures to control them.
Curative effect of heat-sensitive moxibustion on chronic persistent asthma: a multicenter randomized controlled trial

Rixin Chen,Mingren Chen,Jun Xiong,Zhenhai Chi,Bo Zhang,Ning Tian,Zhenhua Xu,Tangfa Zhang,Wanyao Li,Wei Zhang,Xiaofeng Rong,Zhen Wang,Gang Sun,Baohe Ge,Guoxiong Yu,Nanchang Song

DOI: https://doi.org/10.1016/s0254-6272(14)60025-x

Abstract:Objective: To compare the curative effects of heat-sensitive moxibustion with conventional drugs on chronic persistent asthma and seek a valuable therapy to replace Western Medicine. Methods: The participants in this multi-center, randomized, and controlled study were randomly divided into two groups: group A (n=144), treated with heat-sensitive moxibustion (50 sessions) and group B (n=144), treated with Seretide (salmeterol 50 plg/fluticasone 250 pg, twice a day). The scores of asthma control test (ACT), forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF), and attack frequency were measured after 15, 30, 60, and 90 days of treatment. Patients followed up 3 and 6 months after treatment. Results: There was a significant difference (P= 0.0002) in the ACT score and lung function between the two groups after 3 months of treatment and (P=0.000 03) during the follow-up visits. In addition, heat-sensitive moxibustion reduced attack frequency in the period from inclusion to the 6-month follow-up visit. Conclusion: This study shows that heat-sensitive moxibustion may have a comparable curative effect to Seretide (salmetero/fluticasone) on asthma.
The efficacy and safety of moxibustion for chemotherapy-induced gastrointestinal adverse reaction: A protocol for systematic review and meta-analysis

Han-Xiao Zhang,Cheng-Shun Zhang,Xiao-Qin Dai,Chuan-Yi Zuo,Peng Lv,Rui-Zhen Huang,Qian-Ning Mo,Yi-Feng Bai,Yi Zhou

DOI: https://doi.org/10.1097/MD.0000000000022042

2020-08-28

Abstract:Background: Many cancer patients experience gastrointestinal adverse reaction during chemotherapy. Pharmacological interventions are commonly used to treat chemotherapy-induced gastrointestinal side effects but have various limitations. Clinical trials have indicated that moxibustion may alleviate gastrointestinal dysfunction and improve quality of life (QoL) after chemotherapy. This study aims to assess the efficacy and safety of moxibustion for chemotherapy-induced gastrointestinal adverse reaction through a systematic review and meta-analysis. Methods: All randomized controlled trials (RCTs) related to moxibution targeting chemotherapy-induced gastrointestinal adverse reaction will be searched in online databases, such as PubMed, EMBASE, the Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), the Chinese Scientific Journal Database (VIP Database) and WanFang Database from their inception to May 1, 2020. The primary outcome is the incidence and severity of chemotherapy-related gastrointestinal toxicities (nausea and vomiting, diarrhea and constipation). The secondary outcomes include the quality of life, biological parameters' alteration, and adverse events. Study selection, data extraction, and assessment of risk of bias will be performed independently by 2 researchers. The Cochrane Collaboration's Review Manager (RevMan 5.3) software will be used to conduct the direct meta-analysis. Results: This study will provide a comprehensive review of the available evidence for the treatment of chemotherapy-induced gastrointestinal adverse reaction with moxibustion. Conclusion: The conclusion of this study will provide evidence to judge whether moxibustion is an effective and safety therapeutic intervention for chemotherapy-induced gastrointestinal adverse reaction. Prospero registration number: CRD42020182990.
[Effects of Moxibustion at "Feishu"(BL 13) and "Shenshu"(BL 23) on Peripheral Blood T Cells and Serum Interleukin in Asthmatic Rats].

Hai He,Xiang-hua Chen

2017-04-25

Abstract:OBJECTIVE To observe the effect of moxibustion at "Feishu" (BL 13) and "Shenshu"(BL 23) on peripheral blood T cells and serum interleukin in rats with asthma, so as to explore its immunological mechanisms in relieving asthma. METHODS Thirty SD rats were randomly divided into normal, model and moxibustion groups(10 rats/group). Asthma model was established by intraperitoneal injection of ovalbumin and aluminum hydroxide, and ovalbumin inhalation. Moxibustion was applied to bilateral "Feishu" (BL 13) and "Shenshu"(BL 23) for 30 min, once daily for 14 d. The pathologic changes of the lung tissue were detected by H.E. staining. The levels of CD 3+, CD 4+, CD 8+ T cells in whole blood were detected by flow cytometry. Serum IgE, IL-1 β, IL-1 Ra contents were assayed by ELISA (enzyme-linked immunosorbent assay). RESULTS The thickened muscle of bronchial wall, mucosal edema, infiltration of inflammatory cells and partial destruction of the alveolar structure were found in the model group. While in the moxibustion group, the structure of the alveolar wall was complete, the morphology of the bronchioles was regular, and there were no mucus plug formation and epithelial cell shedding in the lumen. The contents of blood CD 8+ and CD 3+ T cells, and serum IgE and IL-1 β in the model group were obviously higher than those in the normal group (P<0.01). Compared with the model group, the levels of blood CD 8+ T cell, serum IgE and IL-1 β in the moxibustion group were all decreased (P<0.05,P<0.01), meanwhile the levels of blood CD 4+ T cell and serum IL-1 Ra were increased (P<0.01,P<0.05). CONCLUSIONS Moxibustion can reduce the levels of serum IgE and IL-1 β, and increase the level of serum IL-1 Ra, which may play an important role in the treatment of asthma.

Medicine
Efficacy and safety of community-based moxibustion for primary hypertension: A randomized controlled trial with patient preference arms

Xu Zhou,Qiuyun Xue,Jianyu You,Shuqing Li,Ling Li,Weifeng Zhu,Yong Fu,Xin Sun

DOI: https://doi.org/10.1111/jch.14738

Abstract:Moxibustion has been shown to have a potential antihypertensive effect, but its applicability for the primary care of hypertension is unclear. The authors conducted a multicenter randomized controlled trial (RCT) with patient preference arms to investigate the effect, safety, cost-effectiveness, and compliance of moxibustion in community patients with hypertension. Patients with primary hypertension were enrolled from seven communities randomly or nonrandomly assigned to receive self-administered moxibustion + the original hypertensive regimen or the original hypertensive regimen alone for 6 months. The authors mainly evaluated the effects of moxibustion on hypertensive outcomes and adverse events. As a result, a total of 160 and 240 patients were recruited into the randomized and nonrandomized arms, respectively, with 87.5% completing the follow-up. At month 6, there was a significantly greater reduction in systolic blood pressure (SBP) (difference: -10.57 mmHg), a higher proportion of responders (82.2% vs. 53.7%; odds ratio 4.00), and better improvements in hypertensive symptoms and quality of life (QoL) in the moxibustion group than in the control group in the randomized population, but there was no significant between-group difference in diastolic blood pressure (DBP). The nonrandomized findings showed the same effect direction for all outcomes, except for DBP. All moxibustion-related adverse events were mild. In conclusion, moxibustion can reduce SBP and improve hypertensive symptoms and QoL in community patients with hypertension, with good safety and low cost, although its effect on DBP remains uncertain. The findings suggest that moxibustion may be an appropriate technique for community primary care of hypertension.
Aspiration biopsy cytology and melanoma.

T. Kline,V. Kannan

DOI: https://doi.org/10.1093/AJCP/77.5.597

1982-05-01

American Journal of Clinical Pathology

Abstract:Fine needle aspiration biopsy cytology (ABC) has proven to be a valuable tool for diagnosis of metastatic and primary melanoma. The ABC of 28 cases was studied and the findings tabulated. Melanin can be verified by Fontana-Masson stain. Additional salient features include cell isolation, anisocytosis, multinucleation, eosinophilic nucleoli, and intranuclear inclusions. Use of all of these cytomorphologic findings will result in accurate diagnosis of melanoma by ABC.
Moxibustion as an Adjuvant Therapy for Cancer Pain: A Systematic Review and Meta-Analysis

DOI: https://doi.org/10.2147/JPR.S396696

IF: 2.8319

2023-02-18

Journal of Pain Research

Abstract:Yan Li, 1, &ast Ensi Hong, 1, 2, &ast Wenguo Ye, 2 Jianyu You 1 1 Jiangxi University of Chinese Medicine, Nanchang, People's Republic of China; 2 The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wenguo Ye, The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi Province, People's Republic of China, Email Jianyu You, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi Province, People's Republic of China, Email Purpose: Pain is one of the most common and feared symptoms among cancer patients. Unrelieved pain denies patients comfort and greatly affects their overall quality of life. Moxibustion is commonly used to manage chronic pain. However, its efficacy on cancer pain remains inconclusive. This study aimed to evaluate the efficacy of moxibustion for cancer pain. Methods: We searched seven databases to obtain articles about moxibustion combined with pharmacotherapy for cancer pain published before November 2022. All data extraction was carried out independently by two investigators. RevMan 5.4 software was used for data analysis. Results: A total of ten trials involving 999 cases were included. The results of the meta-analysis revealed that moxibustion combined with pharmacotherapy was significantly better than drug therapy alone in improving pain relief rate (RR =1.16, 95% CI = [1.04, 1.30], P = 0.01), reducing pain scores (SMD = − 1.43, 95% CI = [− 2.09, − 0.77], P < 0.0001), Shortening the onset of analgesia (MD = − 12.07, 95% CI = [− 12.91, − 11.22], P < 0.00001), prolonging the duration of analgesia (MD = 3.69, 95% CI = [3.21, 4.18], P < 0.00001), and improving quality of life (SMD = 2.48, 95% CI = [0.67, 4.29], P = 0.007). In addition, moxibustion combined with pharmacotherapy can effectively reduce adverse reactions of drugs (RR =0.35, 95% CI = [0.21, 0.57], P < 0.0001). Conclusion: The evidence in this review supports moxibustion as an effective adjuvant therapy for cancer pain management. However, high-quality RCTs are needed to further confirm these findings. Registration Number: PROSPERO CRD42022370942. Keywords: moxibustion, cancer pain, systematic review, meta-analysis Pain is one of the most distressing and common symptoms of cancer patients. Pain can arise both due to the underlying disease and the treatment the patient has been subjected to. 1 According to statistics, more than 70% of cancer patients have experienced pain symptoms, and nearly 50% of these patients are not adequately controlled. 2 Untreated pain may sometimes cause cancer patients to commit suicide or unnecessary emergency department visits and hospitalizations. 3,4 Pain in cancer patients is a growing problem. Pain hinders patient recovery and negatively affects the quality of life, mental health and work prospects of cancer survivors. 5,6 Currently, the management of cancer pain faces many challenges due to the multifactorial and complexity of cancer pain, 7 and the clinical management of cancer pain is mostly based on drugs. 8 Although the three-step analgesic method is effective and recommended by the World Health Organization (WHO), 9 side effects of drug treatment are common, such as constipation, nausea, vomiting, dizziness, and altered cognition. 10,11 Furthermore, certain analgesics, such as opioids, are potential drugs that cause addiction and abuse. 12 Aversion to adverse effects of treatment and fear of developing addiction make many patients seek non-pharmacological treatment. 13–15 In China, moxibustion and acupuncture are the most widely used forms of non-pharmacological treatment, and acupuncture has been recommended by the National Comprehensive Cancer Network clinical practice guidelines as a comprehensive intervention for the management of cancer pain in adults. 16 In addition, the analgesic effects of acupuncture on cancer pain have also been supported by several recent systematic reviews. 17–19 In fact, like acupuncture, moxibustion is also an ancient acupoint stimulation therapy. It involves the application of burning mugwort indirectly or directly at acupoints or other specific areas of the body to prevent or treat diseases. 20 Among the currently available clinical studies on moxibustion for pain, most of them suggest that moxibustion is beneficial for pain patients. 21–23 Moreover, the analgesic effects of moxibustion have als -Abstract Truncated-

clinical neurology
Effects of acupuncture and moxibustion at Feishu (BL13) on inflammatory responses and intestinal short-chain fatty acids in asthma model rats

Zhang, Guoshan

DOI: https://doi.org/10.1007/s11726-024-1435-3

2024-04-19

Journal of Acupuncture and Tuina Science

Abstract:Objective To observe the effects of acupuncture and moxibustion at Feishu (BL13) on inflammatory responses and intestinal short-chain fatty acids (SCFAs) in rats with asthma. Methods Fifty-six Sprague-Dawley rats were randomly divided into a normal group (16 rats) and a modeling group (40 rats). Rats in the modeling group were subjected to establishing asthma models using ovalbumin (OVA). Model evaluation was conducted using 4 rats from each group. The remaining rats that successfully developed asthma were then randomly divided into a model group, an acupuncture group, and a moxibustion group, with 12 rats in each group. Rats in the acupuncture group received acupuncture treatments, and those in the moxibustion group received moxibustion treatments, both at Feishu (BL13) for 30 min. Following the treatments, the rats were exposed to atomization excitation with a 1% OVA solution for 20 min daily for 14 consecutive days. At the end of the experiment, inflammatory markers in the rats' peripheral blood were analyzed using a biochemical method. In addition, inflammatory cells in the bronchoalveolar lavage fluid (BALF) were counted using Wright-Giemsa staining. The lung tissue of rats was examined under a light microscope after staining with hematoxylin-eosin to observe morphological or pathological changes. Furthermore, real-time fluorescence quantitative polymerase chain reaction was utilized to measure the mRNA expression of inflammatory factors in the lung tissue. Lastly, the concentration of SCFAs in the rat's feces was determined using gas chromatography-hydrogen flame ionization. Results The levels of eosinophils (Eos), neutrophils (Neu), and lymphocytes (Lym) in the peripheral blood, as well as Eos and Neu in the BALF, and the expression of interleukin (IL)-4, IL-5, IL-13, IL-33, and thymic stromal lymphopoietin (TSLP) mRNAs in the lung tissue were all found to be significantly increased ( P <0.05 or P <0.01); the lung tissue structure displayed severe injuries; the levels of acetic acid, propionic acid, isobutyric acid, butyric acid, and valeric acid in the feces decreased significantly in the model group ( P <0.05 or P <0.01). Compared with the model group, the peripheral blood levels of Eos, Neu, and Lym, as well as Eos in the BALF, and the mRNA expression levels of IL-4 and IL-5 in the lung tissue decreased significantly in both the acupuncture group and the moxibustion group ( P <0.05 or P <0.01). This reduction was accompanied by alleviated pathological damage in the lung tissue. Additionally, there were significant increases in the levels of acetic acid, propionic acid, isobutyric acid, and butyric acid in the feces in both the acupuncture group and the moxibustion group ( P <0.05 or P <0.01). In the acupuncture group, the expression levels of Lym in the BALF and IL-13 mRNA in the lung tissue decreased significantly ( P <0.05 or P <0.01). In the moxibustion group, the mRNA expression levels of IL-33 and TSLP in the lung tissue also reduced significantly ( P <0.05 or P <0.01). Furthermore, the level of valeric acid in the feces increased notably in the moxibustion group ( P <0.01). Compared with the acupuncture group, it was found that the mRNA levels of IL-5 and IL-13 in the lung tissue, as well as the acetic acid level in the feces, were significantly higher in the moxibustion group ( P <0.05 or P <0.01). Conclusion Both acupuncture and moxibustion were effective in reducing abnormal inflammation and regulating intestinal SCFAs in asthma model rats. Acupuncture demonstrated superiority in inhibiting pro-inflammatory factors, particularly IL-5 and IL-13, while moxibustion exhibited better regulation on intestinal metabolites SCFAs, especially acetic acid.

integrative & complementary medicine
Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group.

P. Fenaux,M. C. L. Deley,S. Castaigne,E. Archimbaud,C. Chomienne,Hartmut,Link,A. Guerci,M. Duarte,Marie ThBrese Daniel,D. Bowen,G. Huebner,F. Bauters,N. Fegueux,M. Fey

DOI: https://doi.org/10.1182/blood.v82.11.3241.bloodjournal82113241

IF: 20.3

Blood

Abstract:We designed a multicenter randomized trial comparing chemotherapy with daunorubicin-Ara C (chemotherapy group) and all transretinoic acid (ATRA) combined to the same chemotherapy (ATRA group) in newly diagnosed APL patients aged 65 years or less. The major endpoint of the study was event-free survival (EFS) ("events" being defined as failure to achieve complete remission [CR], occurrence of relapse, or death in CR). Early termination of the trial was decided after the first interim analysis, as EFS was significantly higher in the ATRA group. At the time, 101 patients had been randomized (54 in the ATRA group and 47 in the chemotherapy group). In the ATRA group, 49 (91%) patients achieved CR, 5 (9%) had early death, and 0 had resistant leukemia, compared with 38 (81%), 4 (8%), and 5 (10%) patients, respectively, in the chemotherapy group. The difference in CR rate between the two groups was not significant. The duration of coagulopathy was significantly reduced in the ATRA group, compared with the chemotherapy group. In the ATRA group, six patients relapsed after 7 to 15.5 months. In the chemotherapy group, 12 patients relapsed after 1 to 16 months, and 2 died in CR. Kaplan-Meier EFS was estimated at 79% +/- 7% and 50% +/- 9% at 12 months, respectively, in the ATRA and the chemotherapy group (P = .001). Kaplan-Meier estimate of relapse was 19% +/- 8% and 40% +/- 12% at 12 months (P = .005). In conclusion, ATRA followed by chemotherapy increases EFS in newly diagnosed APL. These results strongly suggest that ATRA should be incorporated in the front line therapy of newly diagnosed APL.
Leucoderma in chronic graft‐versus‐host disease: excellent repigmentation with noncultured cellular grafting

A. W. Tan,L. Koh,B. Goh

DOI: https://doi.org/10.1111/j.1365-2133.2011.10341.x

IF: 11.113

2011-08-01

British Journal of Dermatology

Abstract:1 Demitsu T, Kakurai M, Yoneda K et al. Localized pemphigoid (Brunsting–Perry type) with IgG antibody to BP180 NC16a domain resembling lupus erythematosus successfully treated with topical tacrolimus therapy. J Eur Acad Dermatol Venereol 2009; 23:79–80. 2 Takeichi S, Kubo Y, Arase S et al. Brunsting–Perry type localized bullous pemphigoid, possibly induced by furosemide administration and sun exposure. Eur J Dermatol 2009; 19:500–3. 3 Tanaka N, Dainichi T, Ohyama B et al. A case of epidermolysis bullosa acquisita with clinical features of Brunsting–Perry pemphigoid showing an excellent response to colchicine. J Am Acad Dermatol 2009; 61:715–19. 4 Joly P, Ruto F, Thomine E et al. Brunsting–Perry cicatricial bullous pemphigoid: a clinical variant of localized acquired epidermolysis bullosa? J Am Acad Dermatol 1993; 28:89–92. 5 Murata Y, Tani M, Kumano K. Localized chronic pemphigoid of Brunsting–Perry. Ultrastructural localization of IgG and complement components. Arch Dermatol 1983; 119:921–4. 6 Honoki K, Muramatsu T, Nakatani C et al. A case of nonscarring inflammatory epidermolysis bullosa acquisita: characterization of IgG autoantibodies by immunofluorescence, immunoblotting and immunogold electron microscopy. J Dermatol 1998; 25:666–72. 7 Jones JC, Hopkinson SB, Goldfinger LE. Structure and assembly of hemidesmosomes. Bioessays 1998; 20:488–94. 8 Hashimoto T, Dainichi T, Ohyama B et al. A case of antilaminin 332 mucous membrane pemphigoid showing a blister on the bulbar conjunctiva and a unique epitope on the alpha3 subunit. Br J Dermatol 2010; 162:898–9. 9 McMillan JR, Shimizu H. Desmosomes: structure and function in normal and diseased epidermis. J Dermatol 2001; 28:291–8. 10 Hashimoto T, Hamada T, Dainichi T et al. How does intramolecular epitope spreading occur in BPAG2 (BP180)? J Invest Dermatol 2010; 130:924–6.
Efficacy and safety of moxibustion on cancer-related fatigue: a systematic review and meta-analysis of randomized controlled trials

Xiao-Qing Wang,Yue Qiao,Pei-Bei Duan,Shi-Zheng Du,Li-Hua Yang,Duan, Pei-Bei

DOI: https://doi.org/10.1007/s00520-023-07977-z

IF: 3.1

2023-08-08

Supportive Care in Cancer

Abstract:The goal of this research was to review the literature from randomized controlled trials (RCTs) on the impacts of moxibustion on cancer-related fatigue (CRF) as well as provide credible evidence to guide clinical practice.

oncology,health care sciences & services,rehabilitation
Using filtrate of waste biosolids to effectively produce bio-hydrogen by anaerobic fermentation.

C. C. Wang,Ching-Wen Chang,C. Chu,Duu-Jong Lee,B. Chang,C. Liao,Joo-Hwa Tay

DOI: https://doi.org/10.1016/S0043-1354(03)00004-6

IF: 12.8

2003-06-01

Water Research

Abstract:
Acupuncture and Moxibustion for Cancer-related Fatigue: a Systematic Review and Meta-analysis

Xi-Ran He,Quan Wang,Ping-Ping Li

DOI: https://doi.org/10.7314/apjcp.2013.14.5.3067

2013-01-01

Asian Pacific Journal of Cancer Prevention

Abstract:Background: Faced with highly prevalent and recalcitrant cancer-related fatigue (CRF), together with the absence of any official guidelines on management, numerous groups have been striving to seek and test alternative therapies including acupuncture and moxibustion. However, different patients have various feedbacks, and the many clinical trials have given rise to varied conclusions. In terms of the therapeutic effect of acupuncture and moxibustion, there exist vast inconsistencies. Objective: The aim of the study was to evaluate the auxiliary effectiveness of acupuncture and moxibustion in the treatment of CRF, and to provide more reliable evidence to guide clinical practice. Methods: Randomized controlled trials (RCTs) published before December 2012 were all aggregated, focusing on evaluation of acupuncture or moxibustion for CRF. The quality of the included studies was assessed basing on Cochrane handbook 5.1.0, and the available data were analyzed with RevMan software (version 5.2.0). Descriptive techniques were performed when no available data could be used. Results: A total of 7 studies involving 804 participants were eligible. With real acupuncture versus sham acupuncture, subjects receiving true acupuncture benefited more in the reduction of fatigue. With real acupuncture versus acupressure or sham acupressure, fatigue level appeared 36% improved in the acupuncture group, but 19% in the acupressure group and only 0.6% with sham acupressure. When real acupuncture plus enhanced routine care was compared with enhanced routine care, the combination group improved mean scores for general fatigue, together with physical and mental fatigue. With real acupuncture versus sham acupuncture or wait list controls, the real acupuncture group displayed significant advantages over the wait list controls at 2 weeks for fatigue improvement and better well-being effects at 6 weeks. When moxibustion plus routine care was compared with routine care alone, the meta-analyses demonstrated the combination had a relatively significant benefit in improving severe fatigue and QLQ-C30. Conclusion: Up to the search date, there exist few high quality RCTs to evaluate the effect of acupuncture and moxibustion, especially moxibustion in English. Yet acupuncture and moxibustion still appeared to be efficacious auxiliary therapeutic methods for CRF, in spite of several inherent defects of the included studies. Much more high-quality studies are urgently needed.
An Overview of Systematic Reviews of Moxibustion for Knee Osteoarthritis

Shao Yin,Fengya Zhu,Zhao Li,Deya Che,Liuying Li,Jie Feng,Lu Zhang,Zhenyi Huo

DOI: https://doi.org/10.3389/fphys.2022.822953

IF: 4

2022-02-03

Frontiers in Physiology

Abstract:Background Currently, many systematic reviews (SRs) of moxibustion as a treatment of KOA have been published. However, the evidence of different SRs of moxibustion to treat KOA has not been comprehensively evaluated. Aim This overview aimed to evaluate the existing results and provide scientific evidence of the effectiveness and safety of moxibustion in the treatment of KOA. Methods We conducted a comprehensive search of Embase, PubMed, Web of Science, Cochrane Library, SinoMed, CNKI, Wanfang, VIP, and other databases until October 31, 2021. A Measurement Tool to Assess Systematic Reviews 2 (AMSTAR-2) was used to assess the methodological quality of SRs. Preferred Reporting Item for Systematic Reviews and Meta-Analyses was used to evaluate the reporting quality, and the risk of bias in SRs was evaluated by ROBIS Tool. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool to determine the strength of evidence and conducted a meta-analysis of the total effectiveness rate. Results Finally, 10 qualified SRs were included, including 57 randomized controlled trials and 5,149 participants. All SRs evaluated by AMASTAR-2 had more than one critical deficiency, so all SRs were rated as critically low. In the PRISMA checklist, the manuscript structures of the included SRs were relatively complete. Including four SRs with a low risk of bias and six with a high risk of bias using the ROBIS tool. In GRADE, two items (6.25%) were rated as high quality, three (9.37%) as medium quality, 17 (53.12%) as low quality and 10 (31.25%) as very low quality. A re-meta-analysis showed that moxibustion and moxibustion combined treatment improved the total effectiveness rate in knee osteoarthritis (risk ratio = 1.17, 95% confidence interval 1.13–1.21, P < 0.001 and risk ratio = 1.13, 95% CI: 1.04–1.23, P < 0.001), with low heterogeneity ( I 2 = 36.3%, P = 0.020, and I 2 = 0.0%, P = 0.956). A total of eight SRs reported adverse events, and no serious adverse events occurred in the moxibustion group and control group. Conclusion Moxibustion seems to be effective in treating KOA. Four SRs reported 10 common discomfort symptoms caused by moxibustion, and these adverse events can spontaneously subside, even can be avoided, therefore, moxibustion for KOA appears to be safe. However, the reliability of the results is reduced by the high risk of bias of the original studies and the low methodological quality of SRs. Therefore, future studies should pay more attention to the quality of the original study and the evidence quality of the SRs to provide more powerful and scientific evidence of the effectiveness and safety of moxibustion treatment of KOA.

physiology
Moxibustion for the side effects of surgical therapy and chemotherapy in patients with gastric cancer: A protocol for systematic review and meta-analysis

Shuqing Li,Jianrong Chen,Yanping Wang,Xu Zhou,Weifeng Zhu

DOI: https://doi.org/10.1097/MD.0000000000021087

2020-07-17

Abstract:Background: Side effects after surgical therapy and chemotherapy of gastric cancer substantially reduce patients' quality of life. This systematic review aims to investigate whether moxibustion, as a complementary treatment, is effective in alleviating side effects in patients with gastric cancer who underwent surgical therapy or chemotherapy. Methods: We will systematically search nine English and Chinese electronic databases to find relevant randomized controlled trials (RCTs) that compare basic treatment with and without moxibustion for treating the side effects induced by surgical therapy or chemotherapy in patients with gastric cancer. The time frame of the search will be from inception to July 1, 2020, and the publication language will not be limited. The literature screening and data extraction will be completed independently by 2 reviewers. The Cochrane risk of bias tool will be used to assess the risk of bias. For the analyses of the side effects of both surgical therapy and chemotherapy, the primary outcomes are defined as the incidence of any side effect, response rate, and quality of life. For the analyses of the side effects of surgical therapy, the secondary outcomes include the incidence of each individual side effect, time to first flatus/defecation/bowel sounds, and length of in-hospital stay. For the analysis of the side effects of chemotherapy, the secondary outcomes include incidence of each individual side effect, white blood cell/red blood cell/platelets counts, and hemoglobin level. R v3.6.2 software will be used to perform the meta-analyses. The quality of evidence will be classified using the Grading of Recommendations Assessment, Development and Evaluation system. Results: This study will provide the first systematic review evidence on the efficacy of moxibustion as adjuvant management for gastric cancer by rigorous quality assessment and appropriate data synthesis. The results will be submitted to a peer-reviewed journal for publication. Conclusion: The findings of this study will provide currently best evidence on moxibustion for patients with gastric cancer who underwent surgical therapy or chemotherapy and may impact clinical practice.PROSPERO registration number: CRD42020169511.
The Efficacy of Moxibustion for Breast Cancer Patients with Chemotherapy-Induced Myelosuppression during Adjuvant Chemotherapy: A Randomized Controlled Study

Yajie Ji,Siyu Li,Xinyue Zhang,Qiong Li,Qing Lu,Weili Chen,Yu Liu,Jiayu Sheng,Hongli Liang,Ke Jiang,Mengting Li,Shanyan Sha,Huangan Wu,Yan Huang,Xiaohong Xue

DOI: https://doi.org/10.1155/2021/1347342

2021-04-25

Abstract:Objective: The randomized controlled clinical trial aims to investigate the clinical efficacy of moxibustion for breast cancer patients with chemotherapy-induced myelosuppression (CIM) during adjuvant chemotherapy. Methods: Surgically resected breast cancer patients were randomly divided into the moxibustion group (MOX; n = 48) and control group (CON; n = 44). Routine adjuvant chemotherapy (every 21 days, 4-8 cycles) and supportive recombinant human granulocyte colony-stimulating factor were given to both groups, while MOX received an additional moxibustion treatment (once daily after each cycle of chemotherapy). Primary endpoints included the grade of myelosuppression in terms of white blood cell (WBC) and absolute neutrophil count (ANC) and the incidence of myelosuppression-related serious adverse events (SAEs). Other measures included treatment compliance, adverse events (AEs), and survival. Results: WBC counts were generally higher in MOX and were dramatically higher than those in CON at the 7th course of chemotherapy (P=0.008), while grade 1 ANC reduction was dramatically lower than that in CON at the 7thcourse of chemotherapy (P=0.006). These effects were particularly significant in patients receiving anthracycline-taxane combination regimens. Moreover, MOX had fewer febrile neutropenia than CON (P=0.051). MOX demonstrated a lower incidence of grade 3-4 myelosuppression (P < 0.05). AEs including grade 2-3 severe nausea, various kinds of pains, and vertigo occurred less frequently in MOX (P < 0.05). No difference in survival was observed between the two groups (P > 0.05). Conclusion: Moxibustion is effective for treating CIM in breast cancer patients during adjuvant chemotherapy, especially for patients receiving high-dose, long-term, and combined chemotherapy regimens. Moxibustion can reduce the incidence of myelosuppression-related SAE and improve the compliance and safety of chemotherapy in breast cancer.
Efficacy of Moxibustion for Cancer-Related Fatigue in Patients with Breast Cancer: A Systematic Review and Meta-Analysis

Hye-Ri Bae,Eun-Ji Kim,Yo-Chan Ahn,Jung-Hyo Cho,Chang-Gue Son,Nam-Hun Lee

DOI: https://doi.org/10.1177/15347354241233226

2024-02-20

Integrative Cancer Therapies

Abstract:Integrative Cancer Therapies, Volume 23, Issue , January-December 2024. Introduction:Breast cancer is the most commonly diagnosed cancer worldwide, and most patients experience fatigue. However, there are no effective treatments for cancer-related fatigue (CRF). Several randomized controlled trials (RCTs) have suggested that moxibustion improves CRF. We conducted a systematic review and meta-analysis to compare the differences in fatigue scale scores, quality of life, and clinical efficacy in patients with breast cancer who developed CRF and did versus did not receive moxibustion.Methods:RCTs were searched in 7 databases using a standardized search method from database inception to March 2023, and RCTs that met the inclusion criteria were selected.Results:Among 1337 initially identified RCTs, 10 RCTs involving 744 participants were selected for this study. The meta-analysis involved assessment of the revised Piper Fatigue Scale scores, Cancer Fatigue Scale scores, Karnofsky Performance Scale scores, Athens Insomnia Scale scores, clinical efficacy, and Qi deficiency syndrome scale scores. Compared with the control, moxibustion was associated with significantly better Piper Fatigue Scale scores (P < 0.0001), quality of life [Karnofsky Performance Scale scores (P < 0.0001)], clinical efficacy (P = 0.0007), and Qi deficiency syndrome scale scores (P = 0.02).Conclusions:Moxibustion improves CRF in patients with breast cancer. The efficacy of moxibustion should be further examined by high-quality studies in various countries with patients subdivided by their breast cancer treatment status.Registration:PROSPERO ID: CRD42023451292

oncology,integrative & complementary medicine

Spectral properties of methyl-2-cis-lachnophyllate

CHARACTERIZATION OF FRACTURES AND MULTIPHASE FLOW IN FRACTURED PERMEABLE ROCKS USING NMR IMAGING TECHNIQUES

Clinical observation of the moxibustion stimulation and moxibustion effect in treating allergic rhinitis on Shangyintang acupoint by mild-warm moxibustion

Moxibustion for Essential Hypertension and Hypertensive Symptoms: A Systematic Review of 18 Randomized Controlled Trials

What is epidemic intelligence, and how is it being improved in Europe?

Curative effect of heat-sensitive moxibustion on chronic persistent asthma: a multicenter randomized controlled trial

The efficacy and safety of moxibustion for chemotherapy-induced gastrointestinal adverse reaction: A protocol for systematic review and meta-analysis

[Effects of Moxibustion at "Feishu"(BL 13) and "Shenshu"(BL 23) on Peripheral Blood T Cells and Serum Interleukin in Asthmatic Rats].

Efficacy and safety of community-based moxibustion for primary hypertension: A randomized controlled trial with patient preference arms

Aspiration biopsy cytology and melanoma.

Moxibustion as an Adjuvant Therapy for Cancer Pain: A Systematic Review and Meta-Analysis

Effects of acupuncture and moxibustion at Feishu (BL13) on inflammatory responses and intestinal short-chain fatty acids in asthma model rats

Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group.

Leucoderma in chronic graft‐versus‐host disease: excellent repigmentation with noncultured cellular grafting

Efficacy and safety of moxibustion on cancer-related fatigue: a systematic review and meta-analysis of randomized controlled trials

Using filtrate of waste biosolids to effectively produce bio-hydrogen by anaerobic fermentation.

Acupuncture and Moxibustion for Cancer-related Fatigue: a Systematic Review and Meta-analysis

An Overview of Systematic Reviews of Moxibustion for Knee Osteoarthritis

Moxibustion for the side effects of surgical therapy and chemotherapy in patients with gastric cancer: A protocol for systematic review and meta-analysis

The Efficacy of Moxibustion for Breast Cancer Patients with Chemotherapy-Induced Myelosuppression during Adjuvant Chemotherapy: A Randomized Controlled Study

Efficacy of Moxibustion for Cancer-Related Fatigue in Patients with Breast Cancer: A Systematic Review and Meta-Analysis